Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Deferred Revenue: 2016-2025

Historic Current Deferred Revenue for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to $3.9 million.

  • Akebia Therapeutics' Current Deferred Revenue was N/A to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year change of. This contributed to the annual value of $43.3 million for FY2023, which is 1058.27% up from last year.
  • As of Q3 2025, Akebia Therapeutics' Current Deferred Revenue stood at $3.9 million, which was down 29.84% from $5.5 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Current Deferred Revenue peaked at $75.8 million during Q1 2022, and registered a low of $1.2 million during Q1 2025.
  • Moreover, its 3-year median value for Current Deferred Revenue was $43.3 million (2024), whereas its average is $26.4 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first spiked by 1,058.27% in 2023, then crashed by 97.18% in 2025.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Current Deferred Revenue stood at $20.9 million in 2021, then slumped by 82.12% to $3.7 million in 2022, then spiked by 1,058.27% to $43.3 million in 2023, then climbed by 1.61% to $43.3 million in 2024, then crashed by 87.22% to $3.9 million in 2025.
  • Its Current Deferred Revenue stands at $3.9 million for Q3 2025, versus $5.5 million for Q2 2025 and $1.2 million for Q1 2025.